HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
C9004 | Gemtuzumab ozogamicin | Mylotarg | 5 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
C9081 | Idecabtagene vicleucel | Abecma | up to 460000000 | Immunotherapy | CAR-T | BCMA | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
NA | Larotrectinib | Vitrakvi | 25mg, 100mg 20mg/ml | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Yes | 2018 | In Use | |||
J0896 | Luspatercept | Reblozyl | 0.25mg | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 2019 | Jul 1, 2020 | In Use | |||
NA | Entrectinib | Rozlytrek | 100mg, 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Yes | 2019 | In Use | |||
J0640 | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 50 mg | Ancillary Therapy | Chemoprotective | Antidote | No | 1952 | Jan 1, 1997 | In Use | ||
J2860 | Siltuximab | Sylvant | 10 mg | Immunotherapy | Monoclonal Antibody | IL-6 | No | 2014 | Jan 1, 2016 | In Use | ||
J9320 | Streptozocin | Zanosar | 1 g | Chemotherapy | Alkylating Agent | Nitrosourea | No | 1982 | Jan 1, 1986 | In Use | ||
J9329 | Tislelizumab-jsgr | Tevimbra | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2024 | Sep 11, 2024 | In Use | ||
J9600 | Porfimer | Photofrin | 75 mg | Chemotherapy | Photosensitizing Agent | Cytotoxin | No | 1995 | Jan 1, 1998 | In Use | ||
C9418 | Cisplatin | Platinol, Platinol-AQ | 10 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
J9065 | Cladribine | Cladribine | per 1 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 1993 | Jan 1, 1995 | In Use | ||
C9423 | Dacarbazine | Dacarbazine | 100 mg | Chemotherapy | Alkylating Agent | Purine Analog | No | 1975 | Jan 1, 2004 | Dec 31, 2005 | No Longer Used | |
J9255 | Methotrexate (Accord) | Methotrexate | 50mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2014 | Dec 7, 2023 | In Use | ||
J9204 | Mogamulizumab-kpkc | Poteligeo | 1mg | Immunotherapy | Monoclonal Antibody | CCR4 | No | 2018 | Oct 1, 2019 | In Use | ||
Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use | ||||
NA | Thalidomide | Thalomid | 200 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
J9298 | Nivolumab & Relatlimab-rmbw | Opdualag | 3mg/1mg | Immunotherapy | Checkpoint Inhibitor, Monoclonal Antibody | PD-1, LAG3 | No | 2022 | Sep 27, 2022 | In Use | ||
NA | Pemigatinib | Pemazyre | 4.5mg, 9mg, 13.5mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Yes | 2020 | In Use | |||
Olutasidenib | Rezlidhia | 150mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2022 | In Use | ||||
J2468 | Palonosetron hydrochloride (avyxa) | Palonosetron hydrochloride (avyxa) | 25 MCG | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2016 | Jun 10, 2024 | In Use | ||
NA | Rucaparib | Rubraca | 200 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
NA | idelalisib | Zydelig | 150 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
NA | idelalisib | Zydelig | 100 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
J9415 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jan 1, 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.